Canadian Cancer Trials Group Bulletins


PRC.3 -- Featured Clinical Trial in the NCI Cancer Bulletin

PRC.3 (CALGB 90203), A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer, was the featured clinical trial in the September 9, 2008 edition of the NCI Cancer Bulletin.

This trial was centrally activated in Canada on October 15, 2007. Thanks go to the Tom Baker Cancer Centre in Calgary and the Clinical Research Unit at Vancouver Coastal Health Authority for being the first sites to locally activate the trial in Canada. Congratulations to Kelly McLachlan and Bernard Eigl of the Tom Baker Cancer Centre for entering the first Canadian patient onto this study. And, thanks go to the Princess Margaret Hospital who is acting as the provincial applicant to get this trial on track to receive Ontario Cancer Research Ethics Board (OCREB) approval shortly.

All interested centres are encouraged to visit the Canadian Cancer Trials Group PRC.3 trial webpage or call Andrea Hiltz, Study Coordinator, at 613-533-6430 for more information.